简体中文
繁體中文
English
Pусский
日本語
ภาษาไทย
Tiếng Việt
Bahasa Indonesia
Español
हिन्दी
Filippiiniläinen
Français
Deutsch
Português
Türkçe
한국어
العربية
Abstract:TOKYO (Reuters) – Japans Takeda Pharmaceutical Co posted a 13% drop in operating earnings for the nine months ended December but kept its profit outlook for the fiscal year unchanged as it works to bolster its drugs pipeline.
Japan's Takeda's profit slips 13%, pipeline bolsters outlook
TOKYO (Reuters) – Japans Takeda Pharmaceutical Co posted a 13% drop in operating earnings for the nine months ended December but kept its profit outlook for the fiscal year unchanged as it works to bolster its drugs pipeline.
For the first three quarters of the year, operating profit slid to 401.9 billion yen ($3.12 billion) from a year earlier when results were boosted by one-time gains on asset sales. Takeda‘s annual operating profit forecast of 530 billion yen already lags a Refinitiv analysts’ consensus forecast of 593.9 billion yen.
The company said core operating profit, which strips out non-recurring items, increased 26% in the nine-month period.
European Union regulators in December approved Takedas vaccine for dengue fever, branded as QDENGA. The vaccine was earlier approved in Indonesia, while U.S. regulators are reviewing it on a priority basis.
Takeda expects the vaccine to generate $700 million to $1.6 billion in sales over the course of several years.
Also in December, the company agreed to buy an experimental psoriasis drug from U.S.-based Nimbus Therapeutics for as much as $6 billion, demonstrating its willingness to spend big to shore up its pipeline as mainstay products lose patent protection.
Until that deal, Takeda had been aggressively cutting debt and selling off non-core assets following its $59 billion takeover of Shire Plc in 2019.
“Our robust cash flow and strong financial position enabled us to make substantive progress in deleveraging even as we continued to invest for growth,” Takeda said in a statement, adding its net debt to core earnings ratio has improved to 2.5 times as of the end of the third quarter.
($1=128.6100 yen)
(Reporting by Rocky Swift; Editing by Kenneth Maxwell and Elaine Hardcastle)
Natural Gas, WTI Oil, Brent Oil – Oil Markets Retreat After EIA ReportCrude Oil Price Update – Attempting to Stabilize after Wednesday‘s Steep PlungeGold Price Forecast XAU/USD – Straddling Fresh 9-Month High after Powell’s Surprisingly Dovish RemarksItaly Demonstrates Economic and Fiscal Resilience but Higher Growth Needed to Reduce DebtBTC Fear & Greed Index Finds Powell Support to Signal $25,000S&P 500 Rallies after Powell Remarks Amid Increasing Bets on Lower Inflation RisksLoadingLoadingLoading
Disclaimer:
The views in this article only represent the author's personal views, and do not constitute investment advice on this platform. This platform does not guarantee the accuracy, completeness and timeliness of the information in the article, and will not be liable for any loss caused by the use of or reliance on the information in the article.